fda tirzepatide update today approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Compounded Semaglutide & Tirzepatide 2025:

Common Side Effects of GLP-1 Agonists While GLP-1 agonists are generally well-tolerated, some individuals may experience side effects, especially during the initial stages of treatment

This constant elevation can cause significant side effects including insulin resistance, carpal tunnel syndrome, fluid retention, and potential concerns about stimulating abnormal tissue growth

The doctor may recommend continuing the current dose for a bit longer, increasing the dose, or considering alternative treatment options if semaglutide does not seem to be effective for that individual

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials